Thursday, 17 April 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 17 April 2025
News

Off-label use adds billions to profits

Posted 8 April 2025 AM

New Australian research has put a figure on the widespread off-label use of GLP-1RA medicines triggering shortages of the diabetes drug in Australia and around the world.

In 2022, around one in three dollars earned by pharmas in the United States for GLP1-RAs intended to treat diabetes came from patients who were non-diabetic. The estimate has a wide margin of error, but is backed up by years-long shortages of the medicines.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (13)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (7)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.